Skip to main content
. 2014 Oct 20;78(5):1043–1049. doi: 10.1111/bcp.12428

Figure 1.

Figure 1

Mean plasma concentration–time profiles of dolutegravir after administration of dolutegravir alone, dolutegravir coadministration with boceprevir (A) and dolutegravir coadministration with telaprevir (B). Inline graphic, dolutegravir (A); Inline graphic, dolutegravir (B); Inline graphic, dolutegravir + boceprevir (A); Inline graphic, dolutegravir + telaprevir (B)